newsfilter
← Latest News
Business Wire·

KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)

Presentations highlight patient preference for sebetralstat, early treatment as the strongest driver of response, and sustained effectiveness with use in clinical trials KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)